Leader’s Advantage Acquisition (LEDR) will allow holders of its initial public offering units to trade shares and warrants separately beginning November 6, 2026.
Separated Class A ordinary shares will trade on the Nasdaq Global Market under LEDR, and separated warrants under LEDRW. Units that are not separated will continue trading under LEDRU. No fractional warrants will be issued upon separation, and only whole warrants will trade. Holders seeking separation must have their brokers contact Odyssey Transfer & Trust Company, the company’s transfer agent.
Leader’s Advantage Acquisition (LEDR) closed the sale of 650,000 additional units through a partial exercise of its IPO over-allotment option.
The units sold at $10.00 each, raising approximately $6,500,000 in additional gross proceeds. The offering now totals 15,650,000 units and $156,500,000 in gross proceeds, before underwriting discounts and estimated offering expenses. Each unit contains one Class A ordinary share and one-half of one redeemable warrant; each whole warrant permits purchase of one Class A ordinary share at $11.50.
The units began trading on Nasdaq Global Market as LEDRU on September 18, 2026. Once separate trading begins, shares and warrants are expected to list as LEDR and LEDRW. The company plans to focus on a healthcare business combination with an established business of scale and first-in-class drug candidates.
Leader’s Advantage Acquisition Corp. (LEDRU) closed its previously announced $150,000,000 initial public offering of 15,000,000 units at $10.00 per unit on September 21, 2026.
The units began trading on September 18, 2026 on the Nasdaq Global Market under the symbol “LEDRU”. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at $11.50 per share. Only whole warrants will trade and be exercisable. Once the securities trade separately, the Class A shares and warrants are expected to trade under “LEDR” and “LEDRW”, respectively.
The company is a healthcare-focused blank check company led by Dr. Paritosh M. Chakrabarti, Dr. Raj Chakrabarti and Edward Krynski, and granted underwriters a 45-day option to purchase up to 2,250,000 additional units.